Skip to main content
. 2020 Apr 15;10(3):401–412. doi: 10.1007/s13555-020-00378-8

Table 2.

Response rates reported in primary analysis (BOLT study) [23]

200 mg sonidegib laBCC: 42 800 mg sonidegib laBCC: 93 200 mg sonidegib mBCC: 13 800 mg sonidegib mBCC: 23
ORR% (95% CI) 43% (28–59) 38% (28–48) 15% (2–45) 17% (5–39)
CR% 5% 0 0 0
Duration of response (median, months) Not reached Not reached Not reached 8.3 (not estimable)
Progression-free survival (median, months) Not reached Not reached 13.1 7.6
Time to tumor response (median, months) 3.9 3.7 4.6 1